There are many treatment options

• shortness of breath

• chest pain

• new or worse cough

• diarrhea or more bowel movements than usual

• stools that are black, tarry, sticky, or have blood or mucus

• severe stomach-area (abdomen) pain or tenderness

• yellowing of your skin or the whites of your eyes

• nausea or vomiting

• pain on the right side of your stomach area (abdomen)

• dark urine

• feeling less hungry than usual

• bleeding or bruising more easily than normal

• rapid heartbeat

• weight loss or weight gain

• increased sweating

• feeling more hungry or thirsty

• urinating more often than usual

• hair loss

• feeling cold

• constipation

• your voice gets deeper

• muscle aches

• dizziness or fainting

• headaches that will not go away or unusual headache

• Change in the amount or color of your urine.

• headache

• fever

• tiredness or weakness

• confusion

• memory problems

• sleepiness

• seeing or hearing things that are not really there (hallucinations)

• seizures

• stiff neck

• rash

• changes in eyesight

• severe or persistent muscle or joint pains

• severe muscle weakness

• low red blood cells (anemia)

• chills or shaking

• shortness of breath or wheezing

• itching or rash

• flushing

• dizziness

• fever

• feeling like passing out

Pembrolizumab is a humanized monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, thereby inhibiting inhibition of the immune response, including anti-tumor immune response. Pembrolizumab is FDA approved for colorectal cancers that are MSI-H in patients with colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Nivolumab is a fully human monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, thereby inhibiting inhibition of the immune response, including anti-tumor immune response. Nivolumab is now FDA approved for colorectal cancer.